EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 23rd, 2023 • Wave Life Sciences Ltd. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”), made and entered into as of November 8, 2022, by and between Wave Life Sciences USA, Inc., a Delaware corporation (“Company”) and a wholly owned subsidiary of Wave Life Sciences Ltd., a Singapore corporation (the “Parent Company”), and Chris Francis (“Executive”).
INVESTOR AGREEMENT By and Between GLAXO GROUP LIMITED AND WAVE LIFE SCIENCES LTD. Dated as of January 26, 2023Investor Agreement • March 23rd, 2023 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
Collaboration And License Agreement by and among Wave Life Sciences USA, Inc., Wave Life Sciences UK Limited and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED December 13, 2022Collaboration and License Agreement • March 23rd, 2023 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), entered into as of December 13, 2022 (the “Execution Date”), is entered into by and among Wave Life Sciences USA, Inc., a corporation organized and existing under the Laws of the State of Delaware (“Wave US”), Wave Life Sciences UK Limited, a private limited company incorporated under the laws of England and Wales (“Wave UK”, and together with Wave US, “Wave”), and GlaxoSmithKline Intellectual Property (No. 3) Limited, a company existing under the laws of England, with offices at 980 Great West Road, Brentford, Middlesex, TW8 9GS (“GSK”). Wave and GSK are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
SHARE PURCHASE AGREEMENT By and Between GLAXO GROUP LIMITED AND WAVE LIFE SCIENCES LTD. Dated as of December 13, 2022Share Purchase Agreement • March 23rd, 2023 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
